INTERIM ANALYSIS OF MAGNIFY PHASE IIIB: INDUCTION R2 FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA (INHL)

• D.J. Andorsky,
• M. Coleman,
• A. Yacoub,
• J.M. Melear,
• S.R. Fanning,
• K.S. Kolibaba,
• F. Lansigan,
• C. Reynolds,
• G. Nowakowski,
• A.L. Et

Affiliations

D.J. Andorsky

Rocky Mountain Cancer Centers, US Oncology Research, Boulder, United States

M. Coleman

Clinical Research Alliance Inc, Weill Cornell Medicine, New York, United States

A. Yacoub

University of Kansas Cancer Center, Westwood, United States

J.M. Melear

Texas Oncology – Austin, US Oncology Research, Austin, United States

S.R. Fanning

Prisma Health, US Oncology Research, Greenville, United States

K.S. Kolibaba

Compass Oncology, US Oncology Research, Vancouver, United States

F. Lansigan

Dartmouth–Hitchcock Medical Center, Lebanon, United States

C. Reynolds

IHA Hematology Oncology Consultants – Ann Arbor, Ypsilanti, United States

G. Nowakowski

Mayo Clinic, Rochester, United States

A.L. Et

Rocky Mountain Cancer Centers, US Oncology Research, Boulder, United States